Combinatietherapie voor prostaatkanker: prostaatspecifieke membranen antigeengerichte , pH-gevoelige nanodeeltjes geladen met doxorubicine en tanshinon
Prostaatkanker is de op één na meest gediagnosticeerde kanker bij mannen. Combinatietherapie tegen kanker met doxorubicine (DOX) en een ander extract van de traditionele Chinese language geneeskunde is een medicijnafgiftesysteem van nanoformaat dat belooft synergetische antikankereffecten te genereren, het behandelingseffect te maximaliseren en resistentie tegen meerdere geneesmiddelen te overwinnen. Het doel van deze studie is om een medicijnafgiftesysteem te construeren voor de gelijktijdige levering van DOX en tanshinones (TAN). Lipide-nanodeeltjes geladen met DOX en TAN (N-DOX/TAN) werden bereid door emulgering en oplosmiddeldiffusiemethode. PSMA-gerichte nanodeeltjes geladen met DOX en TAN (PN-DOX/TAN) werden gesynthetiseerd door een PSMA-gerichte ligand te conjugeren aan N-DOX/TAN. We evalueren de prestaties van dit systeem in vitro en in vivo . PN-DOX/TAN heeft een grootte van 139,7 ± 4,1 nm en een zeta-potentiaal van 11,2 ± 1,6 mV.
De geneesmiddelafgifte van DOX en TAN uit PN-DOX/TAN was veel sneller dan die van N-DOX/TAN. N-DOX/TAN had meer remmend impact op tumorgroei dan N-DOX en N-TAN, wat constant is met de synergetische resultaten en met succes de voordelen benadrukt van het combineren van DOX en TAN in één systeem. PN-DOX/TAN bereikte een hogere opname door LNCaP- cellen (58,9 ± 1,9%), de hoogste tumorweefseldistributie en de meest significante tumorremmingsefficiëntie. De nieuwe nanogeneeskunde biedt een grote belofte voor de dubbele afgifte van geneesmiddelen aan prostaatkankercellen, wat het potentieel aantoont van synergetische combinatietherapie voor prostaatkanker.
Betekenis van hepatitis B-oppervlakteantigeen , IgM/IgG- kernantilichaam en hepatitis B-virus-DNA bij bloeddonoren
Inleiding: Identificatie van dragers van het hepatitis B-virus bij bloeddonoren is noodzakelijk om overdracht van de ziekte by way of bloedtransfusie te voorkomen.
Doel: Vaststellen of bloeddonoren met positieve resultaten voor serologische markers HBsAg en anti-HBc hepatitis B-virus-DNA-dragers waren.
Methoden: 12.745 monsters werden verzameld van zes Ecuadoraanse bloedbanken en geanalyseerd op HBsAg-, anti-HBc- en anti-HBs-infectieuze markers door middel van geautomatiseerde ELISA. Alle monsters die positief testten op één, twee of alle drie de markers werden geanalyseerd met moleculaire technieken om de aanwezigheid van viraal DNA te bepalen.
Resultaten: 27,5% van de monsters die reactief waren voor alleen anti-HBc en 100% van de monsters met positieve resultaten voor HbsAg en IgM/IgG anti-HBc bleken hepatitis B-virus-DNA te bevatten (p = 0,001).
Conclusies: De selectie van infectiemarkers, evenals de detectiemethoden bepalen de resultaten. Het uitvoeren van twee serologische en één moleculaire checks is belangrijk om dragers van het hepatitis B-virus te identificeren en de overdracht ervan te voorkomen.
Introducción: De identificación de portadores del virus de la hepatitis B en donantes de sangrees imperativo para evitar the transmisión de la fermedad a través de transfusiones sanguineas.
Objetivo: Determinar si los donantes de sangre con resultados positivos en los marcadores serológicos HbsAg y anti-HBc eran portadores del ADN del virus de la hepatitis B.
Methoden: Zie 12 745 muestras de seis bancos de sangre ecuatorianos, las cuales fueron analizadas con pruebas serológicas para identificar marcadores infecciosos de HBsAg, anti-HBc, anti-HBs mediante ELISA. Wat zijn de positieve effecten van het virus, de analyse van de moleculaire analyse van de virale presencia del ADN.
Resultaten: Se identificó que 27,5% de las muestras reactivas solo a anti-HBc y 100 % de las muestras con resultados de HBsAg/anti-HBc-IgM/IgG presentaron ADN del virus de la hepatitis B (p = 0.001).
Conclusies: La elección de los marcadores de infección y los métodos de detección outlined los resultados. Het is belangrijk om het virus van hepatitis door middel van overdracht op moleculaire foundation te identificeren en te identificeren.
Description: This MAb recognizes a protein of 56kDa, identified as cytokeratin 6 (CK6). In humans, multiple isoforms of Cytokeratin 6 (6A-6F), encoded by several highly homologous genes, have distinct tissue expression patterns, and Cytokeratin 6A is the dominant form in epithelial tissue. The gene encoding human Cytokeratin 6A maps to chromosome 12q13, and mutations in this gene are linked to several inheritable hair and skin pathologies. Keratins 6 and 16 are expressed in keratinocytes, which are undergoing rapid turnover in the suprabasal region (also known as hyper-proliferation-related keratins). Keratin 6 is found in hair follicles, suprabasal cells of a variety of internal stratified epithelia, in epidermis, in both normal and hyper-proliferative situations. Epidermal injury results in activation of keratinocytes, which express CK6 and CK16. CK6 is strongly expressed in about 75% of head and neck squamous cell carcinomas. Expression of CK6 is particularly associated with differentiation.
Description: This MAb recognizes a protein of 56kDa, identified as cytokeratin 6 (CK6). In humans, multiple isoforms of Cytokeratin 6 (6A-6F), encoded by several highly homologous genes, have distinct tissue expression patterns, and Cytokeratin 6A is the dominant form in epithelial tissue. The gene encoding human Cytokeratin 6A maps to chromosome 12q13, and mutations in this gene are linked to several inheritable hair and skin pathologies. Keratins 6 and 16 are expressed in keratinocytes, which are undergoing rapid turnover in the suprabasal region (also known as hyper-proliferation-related keratins). Keratin 6 is found in hair follicles, suprabasal cells of a variety of internal stratified epithelia, in epidermis, in both normal and hyper-proliferative situations. Epidermal injury results in activation of keratinocytes, which express CK6 and CK16. CK6 is strongly expressed in about 75% of head and neck squamous cell carcinomas. Expression of CK6 is particularly associated with differentiation.
Description: This MAb recognizes a protein of 56kDa, identified as cytokeratin 6 (CK6). In humans, multiple isoforms of Cytokeratin 6 (6A-6F), encoded by several highly homologous genes, have distinct tissue expression patterns, and Cytokeratin 6A is the dominant form in epithelial tissue. The gene encoding human Cytokeratin 6A maps to chromosome 12q13, and mutations in this gene are linked to several inheritable hair and skin pathologies. Keratins 6 and 16 are expressed in keratinocytes, which are undergoing rapid turnover in the suprabasal region (also known as hyper-proliferation-related keratins). Keratin 6 is found in hair follicles, suprabasal cells of a variety of internal stratified epithelia, in epidermis, in both normal and hyper-proliferative situations. Epidermal injury results in activation of keratinocytes, which express CK6 and CK16. CK6 is strongly expressed in about 75% of head and neck squamous cell carcinomas. Expression of CK6 is particularly associated with differentiation.
Description: LY-411575 is a potent inhibitor of ?-secretase with IC50 value of 0.078 nM in membrane assay.[1]?-Secertase is one of intramenbrane-cleaving aspartyl protease which cleaves many type-I membrane proteins and many of them have important biological functions.
Description: LY-411575 is a potent inhibitor of ?-secretase with IC50 value of 0.078 nM in membrane assay.[1]?-Secertase is one of intramenbrane-cleaving aspartyl protease which cleaves many type-I membrane proteins and many of them have important biological functions.
Description: LY-411575 is a potent inhibitor of ?-secretase with IC50 value of 0.078 nM in membrane assay.[1]?-Secertase is one of intramenbrane-cleaving aspartyl protease which cleaves many type-I membrane proteins and many of them have important biological functions.
Description: LY-411575 is a potent inhibitor of ?-secretase with IC50 value of 0.078 nM in membrane assay.[1]?-Secertase is one of intramenbrane-cleaving aspartyl protease which cleaves many type-I membrane proteins and many of them have important biological functions.
Description: LY-411575 is a potent inhibitor of ?-secretase with IC50 value of 0.078 nM in membrane assay.[1]?-Secertase is one of intramenbrane-cleaving aspartyl protease which cleaves many type-I membrane proteins and many of them have important biological functions.
Description: LY294002 is a potent inhibitor of class I phosphoinositide 3-kinases (PI3Ks) [1, 2]. It is cell permeable and reversible, and selective against p110?, p110?, p110? and p110?, which acts on ATP binding site of the catalytic subunit.PI3K family is divided into 3 classes: class I, II and III.
Description: LY294002 is a potent inhibitor of class I phosphoinositide 3-kinases (PI3Ks) [1, 2]. It is cell permeable and reversible, and selective against p110?, p110?, p110? and p110?, which acts on ATP binding site of the catalytic subunit.PI3K family is divided into 3 classes: class I, II and III.
Description: LY294002 is a potent inhibitor of class I phosphoinositide 3-kinases (PI3Ks) [1, 2]. It is cell permeable and reversible, and selective against p110?, p110?, p110? and p110?, which acts on ATP binding site of the catalytic subunit.PI3K family is divided into 3 classes: class I, II and III.
Description: LY294002 is a potent inhibitor of class I phosphoinositide 3-kinases (PI3Ks) [1, 2]. It is cell permeable and reversible, and selective against p110?, p110?, p110? and p110?, which acts on ATP binding site of the catalytic subunit.PI3K family is divided into 3 classes: class I, II and III.
Description: Description:IC50 Value:N/ALY303511, an inactive analogue of LY294002, is a mTOR inhibitor that did not inhibit PI3-K.in vitro: 100 ?M LY303511 significantly reduced the fraction of cells in S phase.
Description: Description:IC50 Value:N/ALY303511, an inactive analogue of LY294002, is a mTOR inhibitor that did not inhibit PI3-K.in vitro: 100 ?M LY303511 significantly reduced the fraction of cells in S phase.
Description: Description:IC50 Value:N/ALY303511, an inactive analogue of LY294002, is a mTOR inhibitor that did not inhibit PI3-K.in vitro: 100 ?M LY303511 significantly reduced the fraction of cells in S phase.
Description: IC50 Value: 6 nM?Ki? LY344864 is a selective receptor agonist with an affinity of 6 nM (Ki) at the recently cloned 5-HT1F receptor. It possesses little affinity for the 56 other serotonergic and non-serotonergic neuronal binding sites examined [1].
Description: IC50 Value: 6 nM?Ki? LY344864 is a selective receptor agonist with an affinity of 6 nM (Ki) at the recently cloned 5-HT1F receptor. It possesses little affinity for the 56 other serotonergic and non-serotonergic neuronal binding sites examined [1].
Description: IC50 Value: 6 nM?Ki? LY344864 is a selective receptor agonist with an affinity of 6 nM (Ki) at the recently cloned 5-HT1F receptor. It possesses little affinity for the 56 other serotonergic and non-serotonergic neuronal binding sites examined [1].
Description: IC50 Value: 6 nM?Ki? LY344864 is a selective receptor agonist with an affinity of 6 nM (Ki) at the recently cloned 5-HT1F receptor. It possesses little affinity for the 56 other serotonergic and non-serotonergic neuronal binding sites examined [1].
Description: LY 379268 is a highly selective group II mGlu receptor agonist with EC50 value of 2.69 and 4.48 nM for hmGlu2 and hmGlu3, respectively [1].
Description: LY 379268 is a highly selective group II mGlu receptor agonist with EC50 value of 2.69 and 4.48 nM for hmGlu2 and hmGlu3, respectively [1].
Kan gecombineerde multiparametrische magnetische resonantiebeeldvorming van de prostaat en prostaatspecifieke antigeendichtheid de detectie van klinisch significante prostaatkanker verbeteren: een prospectieve single-center cross-sectionele studie
Doel: Het doel van de studie was om PIRADS v2 te valideren op 3T MRI met secundaire beoordeling als combinatie van de PIRADS v2 en PSA-dichtheid de detectie van klinisch significante prostaatkanker verbetert.
Materialen en methoden: We hebben een prospectieve studie uitgevoerd bij 58 patiënten met een PSA-waarde van >Four ng/ml van juli 2017 tot december 2019. Transrectale echografie (TRUS) geleide gerichte biopsie werd uitgevoerd by way of cognitieve focusing on gevolgd door systemische 12 core biopsie. Twee cognitieve fusiegerichte biopsiekernen werden toegevoegd voor elke laesie bij patiënten met verdachte of twijfelachtige laesies op mpMRI. Het PI-RADS scoresysteem versie 2.0 (PI-RADS v2) werd gebruikt om de MRI-bevindingen te beschrijven.
Resultaten: In totaal werden 112 laesies van 58 patiënten beoordeeld by way of mpMRI gevolgd door TRUS-geleide biopsie. Een PI-RADS v2-score van ≥Four ongeacht de PSA-dichtheidscategorieën en een PI-RADS v2-score van Three met een PSA-dichtheid van ≥0,15 ng/ml/cc, leverde de hoogste totale prostaatkanker en klinisch significante detectie van prostaatkanker op. In tegenstelling tot een PI-RADS v2-score van ≤ Three en een PSA-dichtheid van < 0,15 ng/ml/ml (groep met laag risico), die geen klinisch significante prostaatkanker opleverde.
<sturdy class=”sub-title”> Conclusie: </sturdy> Zowel de PIRADS v2-score als de PSA-dichtheid zijn bij uitstek gevoelig en specifiek in de detectie van klinisch significante prostaatkankers afzonderlijk. De combinatie van PIRADS v2 en PSA-dichtheid verbeterde echter de nauwkeurigheid van klinisch significante detectie van prostaatkanker. Patiënten met een combinatie van PIRADS v2-score <sup>3</sup>Three en PSA-dichtheid <sup>3</sup>0,15 ng/ml/cc dienen een prostaatbiopsie te ondergaan.
Productie van monoklonale, van haaien afgeleide immunoglobuline nieuwe antigeenreceptor -antilichamen met behulp van het expressiesysteem van de eierstokcellen van de Chinese language hamster
Kraakbeenvissen zoals haaien hebben een adaptief immuunsysteem op foundation van immunoglobulinen die vergelijkbaar zijn met die van zoogdieren. Tijdens hun evolutie hebben kraakbeenvissen individueel hun adaptieve immuunsysteem verworven, de zogenaamde immunoglobuline nieuwe antigeenreceptor (IgNAR’s). IgNAR’s behouden hun functies in de barre omgeving van haaienserum, dat een hoge concentratie ureum bevat om waterverlies in zeewater te voorkomen . Daarom hebben IgNAR’s een hoge structurele stabiliteit en wordt verwacht dat ze worden gebruikt als antilichamen van de volgende generatie in andere toepassingen dan die van conventionele IgG-antilichamen. Er is echter nog geen recombinant expressiesysteem voor IgNAR, dat een molecuulgewicht heeft van ongeveer 147 kDa als een dimeer en meerdere N-glycosyleringsplaatsen, geconstrueerd. Dit is vastgelopenonderzoek naar de ontwikkeling van IgNAR .
Hier hebben we een recombinant expressiesysteem voor IgNAR geconstrueerd met behulp van ovariumcellen van Chinese language hamsters (CHO), die veel worden gebruikt als gastheren voor de productie van IgG-antilichamen . Met behulp van dit systeem werd IgNAR met succes tot expressie gebracht en gezuiverd als een humaan IgG Fc-fusie-eiwit en vertoonde het antigeenbindend vermogen. Na zuivering van eiwit A-affiniteit, gevolgd door specifieke splitsing en verwijdering van het menselijke Fc-gebied, was de uiteindelijke opbrengst aan IgNAR 1,07 mg/L-medium. Bovendien wijzigde dit CHO-celexpressiesysteem IgNAR met verschillende N-glycanen, waaronder hoge mannose- en complexe typen. Met dit expressiesysteem kunnen we de structuur en de fysisch-chemische eigenschappen analyserenen biologische functies van IgNAR. Deze fundamentele informatie zal de ontwikkeling van IgNAR’s voor industriële en biotechnologische toepassingen bevorderen.
Description: The nucleocapsid of hepatitis B virus is covered by an envelope of HBV surface antigen (HBsAg), which has the common, group-specific determinant a.
Description: The nucleocapsid of hepatitis B virus is covered by an envelope of HBV surface antigen (HBsAg), which has the common, group-specific determinant a.
Description: The nucleocapsid of hepatitis B virus is covered by an envelope of HBV surface antigen (HBsAg), which has the common, group-specific determinant a.
Description: The nucleocapsid of hepatitis B virus is covered by an envelope of HBV surface antigen (HBsAg), which has the common, group-specific determinant a.
Description: A competitive ELISA for quantitative measurement of Goat Hepatitis B surface Antigen in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Goat Hepatitis B surface Antigen in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Goat Hepatitis B surface Antigen in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Rabbit Hepatitis B surface Antigen in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Rabbit Hepatitis B surface Antigen in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Rabbit Hepatitis B surface Antigen in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Human Hepatitis B surface Antigen in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Human Hepatitis B surface Antigen in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Human Hepatitis B surface Antigen in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Mouse Hepatitis B surface Antigen in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Mouse Hepatitis B surface Antigen in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Mouse Hepatitis B surface Antigen in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Porcine Hepatitis B surface Antigen in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Porcine Hepatitis B surface Antigen in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Porcine Hepatitis B surface Antigen in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Monkey Hepatitis B surface Antigen in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Monkey Hepatitis B surface Antigen in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Monkey Hepatitis B surface Antigen in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Rat Hepatitis B surface Antigen in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Rat Hepatitis B surface Antigen in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Rat Hepatitis B surface Antigen in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Canine Hepatitis B surface Antigen in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Canine Hepatitis B surface Antigen in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Canine Hepatitis B surface Antigen in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: Premade ready to use kits will always come in handy. Get your experiment done right form the first try by using a validated kit with perfectly balanced reagents proportions and compatibility and by following a clear protocol.
Hepatitis B Surface Antigen adw Subtype, rHBsAgadw
Description: Premade ready to use kits will always come in handy. Get your experiment done right form the first try by using a validated kit with perfectly balanced reagents proportions and compatibility and by following a clear protocol.
Recombinant Hepatitis B Surface Antigen ayw subtype, Saccharomyces
Description: A competitive ELISA for quantitative measurement of Guinea pig Hepatitis B surface Antigen in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Guinea pig Hepatitis B surface Antigen in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Guinea pig Hepatitis B surface Antigen in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: The QuickTiter Hepatitis B Surface Antigen ELISA Kit measures HBsAg with sensitivity as low as 1 ng/mL. Reagents are sufficient for 96 wells including standards and unknown samples.
QuickTiter Hepatitis B Surface Antigen (HBsAg) ELISA Kit
Description: The QuickTiter Hepatitis B Surface Antigen ELISA Kit measures HBsAg with sensitivity as low as 1 ng/mL. Reagents are sufficient for 5x96 wells including standards and unknown samples.
Human hepatitis B virus surface antigen,HBsAg ELISA Kit
Description: Qualitative sandwich ELISA kit for measuring Mouse hepatitis B virus surface antigen, HBsAg in samples from serum, plasma. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.
Mouse hepatitis B virus surface antigen, HBsAg ELISA Kit
Description: Qualitative sandwich ELISA kit for measuring Mouse hepatitis B virus surface antigen, HBsAg in samples from serum, plasma. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.
Canine hepatitis B virus surface antigen, HBsAg ELISA Kit
Description: Qualitative sandwich ELISA kit for measuring Canine hepatitis B virus surface antigen, HBsAg in samples from serum, plasma. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.
Canine hepatitis B virus surface antigen, HBsAg ELISA Kit
Description: Qualitative sandwich ELISA kit for measuring Canine hepatitis B virus surface antigen, HBsAg in samples from serum, plasma. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.
Human hepatitis B virus surface antigen, HBsAg ELISA Kit
Description: Qualitative sandwich ELISA kit for measuring Human hepatitis B virus surface antigen, HBsAg in samples from serum, plasma. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.
Human hepatitis B virus surface antigen, HBsAg ELISA Kit
Description: Qualitative sandwich ELISA kit for measuring Human hepatitis B virus surface antigen, HBsAg in samples from serum, plasma. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.
Mouse hepatitis B virus surface antigen,HBsAg ELISA Kit
Description: A sandwich ELISA kit for quantitative measurement of Human HBsAg (Hepatitis B surface antigen) in samples from Serum, Plasma, Cell supernatant
Human hepatitis B virus surface antigen(HBsAg)ELISA Kit
Description: Enzyme-linked immunosorbent assay kit for quantification of Canine hepatitis B virus surface antigen,HBsAg in samples from serum, plasma, tissue homogenates and other biological fluids.
ELISA kit for Human hepatitis B virus surface antigen,HBsAg
Description: Enzyme-linked immunosorbent assay kit for quantification of Human hepatitis B virus surface antigen,HBsAg in samples from serum, plasma, tissue homogenates and other biological fluids.
ELISA kit for Mouse hepatitis B virus surface antigen,HBsAg
Description: Enzyme-linked immunosorbent assay kit for quantification of Mouse hepatitis B virus surface antigen,HBsAg in samples from serum, plasma, tissue homogenates and other biological fluids.
HbsAg ELISA Kit| Mouse Hepatitis B Surface Antigen ELISA Kit
Description: Quantitative sandwich ELISA for measuring Human Hepatitis B surface antigen (HBsAg) Kit in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
ELISA kit for Human Hepatitis B surface antigen (HBsAg) Kit
Description: Quantitative sandwich ELISA for measuring Human Hepatitis B surface antigen (HBsAg) Kit in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
ELISA kit for Human Hepatitis B surface antigen (HBsAg) Kit
Description: Quantitative sandwich ELISA for measuring Human Hepatitis B surface antigen (HBsAg) Kit in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Recombinant (Yeast) purified Hepatitis B surface Antigen (HBsAg, Ad/Ay)
